chrisvoncsefalvay/vaers-outcomes huggingface dataset:
swollen lymph node in injection arms; swollen lymph nodes in neck.; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE LYMPHADENOPATHY (swollen lymph node in injection arms) and LYMPHADENOPATHY (swollen lymph nodes in neck.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unk) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE LYMPHADENOPATHY (swollen lymph node in injection arms) and LYMPHADENOPATHY (swollen lymph nodes in neck.). At the time of the report, VACCINATION SITE LYMPHADENOPATHY (swollen lymph node in injection arms) and LYMPHADENOPATHY (swollen lymph nodes in neck.) outcome was unknown.            No concomitant medication is reported. No treatment medication is reported.   This case was linked to MOD-2021-154673 (Patient Link).   Reporter did not allow further contact
On 3/11/21, patient had a CVA, resulting in hospitalization. Testing during admission indicated a need for a carotidectomy. Pt had the procedure on 3/17/21, when a second CVA occurred. Pt has returned home, but requires assistance with ADL's. Family notes that patient had an ultrasound of  arteries completed January of 2021, results were "normal".
doses administered past the published expiry date; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date). On 11-Oct-2021, EXPIRED PRODUCT ADMINISTERED (doses administered past the published expiry date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   product removed from freezer 8AM No treatment information was provided. No concomitant medication was provided.
pt reported experienceing pain in rt deltoid 6 days p/inject; applied moist heat 1x on 18NOV94 & began taking Ibuprofen; 9NOV94 sterile abscess 10mm on rt deltoid over inject site; streaks of erythema & heat in surrounding area;  pruritus;
This spontaneous report as received from a medical assistant refers to unspecified patients of unknown age and gender. There were no concomitant medications, concurrent condition and medical history reported. On unknown dates, the patients were inadvertently administered with 10 doses of improperly stored VAQTA lot # K005958 (dose and expiration date were not reported). No adverse effects were reported. Additional information has been requested.
vaccine exposure during pregrenancy; This spontaneous prospective pregnancy case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregrenancy) in a 31-year-old female patient (gravida 3, para 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011j20A) for COVID-19 vaccination.     The patient's past medical history included C-section (placental abruptions,low line placenta, live full term birth) on 01-Jun-2017 and C-section (high risk pregnancy, low line placenta,live full term birth) on 01-May-2019. Concurrent medical conditions included Drug allergy (flajyl), Asthma (late onset; flare up during second pregnancy) since 01-Jan-2006 and Allergy (Seasonal). Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for Allergy, SALBUTAMOL (ALBUTEROL HFA) and MONTELUKAST SODIUM (SINGULAIR) for Asthma, CAVAN EC SOD DHA PRENATAL VITAMINS and PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Pregnancy.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 15-Nov-2020 and the estimated date of delivery was 22-Aug-2021. On 21-Dec-2020, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregrenancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eighth week of the pregnancy.  On 21-Dec-2020, MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregrenancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Dec-2020, Pregnancy test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Estimated date of conception was 15 Nov 2020 . treatment information provided.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
A pharmacist reported the occurrence of flu-like symptoms in a 37 y.o. female who was vaccinated with Hep B vaccine recombinant (Engerix-B). The subject's medical history, concurrent medications were not specified. On 9/11/02 or 9/12/02, the subject received her first injection of Hep B vaccine recombinant (Engerix-B). The subject experienced flu-like symptoms, muscle aches, backaches, diarrhea, upset stomach with gas or abdominal cramps, and possibly a low grade fever. The outcome for these events was reported as unresolved.
Left arm erythema and induration noted on the day after the DTAP administration involving the lower 1/2 of the left upper arm. Full normal range of motion, mildly tender. No fever.
Erythema, swelling, pain at injection site, headache, diarrhea still persisting 6 days post injection (not resolved). Also fatigue, upset stomach, malaise.
Information has been received from a nurse referring to multiple unspecified patients of unknown age and gender. There was no pertinent medical history, concurrent conditions, concomitant medications or drug allergies/drug reactions described. On unknown dates, the patients were administered improperly stored VAQTA (Lot # L043209 with expiration date of 17-SEP-2017), (dose and route were not reported), which were stored at 1.8 C for 1 hour and 45 minutes. The vaccines did not have previous temperature excursion. No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old male patient received BNT162b2 (BNT162B2), on 05Sep2021 as dose number unknown, single (Batch/Lot number: unknown) at the age of 52 years for COVID-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive; positive, notes: Rebound COVID today, symptomatic and testing positive. Therapeutic measures were taken as a result of drug ineffective, COVID-19. Other medication in two week was reported as unknown. Patient started Paxlovid on 11May2022 and stopped on 15May2022for the treatment of COVID-19. Vaccine lot no was not available/ provided to the reporter at the time of report completion.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Severe pain left arm radiating from deltoid area to fingertips.  Treated with ice and Motrin 800mg q 8 hour.  Pain decreased in 48 hours.  As pain decreased, numbness noted in left 3rd, 4th, 5th fingers.  As of 09/29/2010 2:00 PM there is no pain, but numbness remains.
4AUG91 sore throat, nausea; 5AUG91 swollen neck glands, sore throat, stuffy nose; 6AUG91 chills; 8AUg91 rash fine pinpoint all over; 9AUG91 rash gone felt okay;
Erythema Nodosum on lower legs; This is a spontaneous report from a contactable other hcp (patient). A 16-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Lot number: unknown) via an unspecified route of administration in left arm on 27Mar2021 at 08:00 (age at vaccination 16-year-old) as dose 1, single and received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Lot number: unknown) via an unspecified route of administration in left arm on 17Apr2021 at 08:00 (age at vaccination 16-year-old) as dose 2, single for Covid-19 immunization at hospital. Patients relevant medical history was none. Patient did not have any known allergies. Patients concomitant medications included doxycycline and muslin birth control. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Mar2021, patient took Varicella vaccine as dose 1 in left arm for immunization. On 12Apr2021, at 20:00 patient experienced Erythema Nodosum on lower legs. Adverse event resulted into doctor or other healthcare professional office/clinic visit. Patient received treatment of elevating legs for adverse event. Since the vaccination, the patient had been tested for COVID-19. The patient underwent lab tests and procedures which included Rapid Covid test (sars-cov-2 test, Nasal Swab): negative on 06May2021. The outcome of event was not recovered.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and the event erythema nodosum cannot be completely excluded.  The impact of this report on the benefit-risk profile of the Pfizer product and on the conduct of the study is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, ethics committees. and investigators, as appropriate.
aAms and legs are feeling weak; Feeling light fatigue; Slight headache along his eyebrows; Very mild sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Very mild sore arm), MUSCULAR WEAKNESS (aAms and legs are feeling weak), FATIGUE (Feeling light fatigue) and HEADACHE (Slight headache along his eyebrows) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Aug-2021, the patient experienced PAIN IN EXTREMITY (Very mild sore arm). On 10-Aug-2021, the patient experienced HEADACHE (Slight headache along his eyebrows). On 11-Aug-2021, the patient experienced MUSCULAR WEAKNESS (aAms and legs are feeling weak) and FATIGUE (Feeling light fatigue). At the time of the report, PAIN IN EXTREMITY (Very mild sore arm) and HEADACHE (Slight headache along his eyebrows) outcome was unknown and MUSCULAR WEAKNESS (aAms and legs are feeling weak) and FATIGUE (Feeling light fatigue) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant or treatment medications were provided. No treatment information was reported.
Generalized Lymphadenopathy; This is a spontaneous report from a contactable physician (patient). A 34-years-old female patient (not pregnant) received first dose bnt162b2 (lot number: EH9899) (Pfizer BioNTech COVID-19 Vaccine), intramuscular on 21Dec2020 08:00 on left arm at single dose for COVID-19 immunization. Medical history included penicillin. No other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19 prior to vaccination. The patient's concomitant medications were not reported. The patient experienced generalized lymphadenopathy on 21Dec2020. No treatment received for the event. Outcome of event was not recovered. Since the vaccination the patient has not been tested for COVID-19.
Grandmother, who is pt's guardian, called clinic to report that pt woke up with hives on his arms and legs that were very itchy the morning after the flu shot was given. Grandmother is giving Benadryl with temporary relief. No difficulties breathing or swallowing. Pt advised to go to UC at that time but to ED if having difficulties breathing. Grandmother called back the next day stating pt went to UC and received treatment with steroids but that s/s were returning. Sent pt back to UC where pt received further treatment for an allergic reaction. Pt was seen in clinic as a f/u on 3/31/16 with Dr.
Patient is fully vaccinated. COVID +. 57-year-old female, who has a history of breast carcinoma and is currently undergoing chemotherapy.  She was admitted after developing fever withnonproductive cough and sore throat earlier on the day of admission. Additionally, she is leukopenic due to her chemo and had a white blood cell count on admission of 0.7 with 0.2% neutrophils. Her chest x-ray was negative for infiltrates on admission and she has not been hypoxemic, having normal O2 saturations on room air.  She was febrile to 101.6 degrees. No current indication for Remdesivir or baricitinib.  Antibiotics given. Patient discharged home.
stomach cramps that started a few hours after the vaccination followed by diarrhea.  Itchy angry reddish bumps that started on right side (waist high) and then spread to middle back, upper right forehead, then scalp.  A few bumps also on leg.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On 21-MAY-2013, the patient was inoculated with ZOSTAVAX at the Pharmacy for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On 28-AUG-2016, the patient was treated by a healthcare professional and was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life, increased risk of premature death, aggravation of pre-existing conditions and activation of latent conditions; lost wages; loss of earnings capacity, and other losses and damages. And pain and suffering, and other damages. At the time of the report, the outcome of the aforementioned adverse events was unknown, excepting for the events of emotional distress and pain that was reported as not resolved. The relatedness assessment between the aforementioned adverse events and ZOSTAVAX was related. The reporter considered the events as serious for the following reasons: Hospitalization, life-threatening, disability and medical significant.
For 3 days after the injection I had fever, fatigue, headache, chills, muscle/ joint pain, nausea, diarrhea and injection sit pain, redness, and swelling. Then all the symptoms except for diarrhea went away for 2 weeks.  I have a history of IBS, so diarrhea isn't uncommon for me, but I don't typically have it everyday like I am now.  On February  8 I began having fatigue and headache.  On February 10, my left arm became red, swollen, painful and hot again, just like after the injection. By Feb 11, I started having nausea, more severe fatigue/ headache, chills and I developed a low grade fever @ 100.9.  Since then, I have continued to have these symptoms. They are intermittent as far as severity.  When my arm really hurts, I'm very nauseated, fatigued, my headache is severe and I typically have a low grade fever.  I've also noticed hives on my arm, chest and neck intermittently since Feb 11.  I have a history of hives too, but this is usually after eating certain foods.  On Feb 11 when I got hives, I hadn't eaten for many hours (I was nauseated) and that is very atypical for me.  For treatment, I got a covid for test done on 2/12 that was negative, and I took motrin yesterday for increasing headache, arm pain and fever.
On day 2 went to er documented on monitor.  guillan barre syndrome on day 9 went to hospital and admitted from 9/15-9/20 for progressive numbness and tingling in feet and hands
Follow up: Patient received casirivimab instead of intended COVID vaccine.  At 48-hr follow up, patient reported arm soreness. Patient received COVID vaccine on December 31
Information has been received from an infectious disease physician concerning an 11 year old male pt who on 08JAN2004 was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine. Subsequently on 08JAN2004, the pt developed a local rxn below the injection site (pain and swelling) and a fever of 102 F. Unspecified medical attention was sought, but treatment was not required. As of 12JAN2004, the fever was gone and the pain and swelling were greatly reduced. A product quality complaint was not involved Additional information has been requested.
Pt reporting fatigue, tingling and numbness in arms, hands, feet and pain in neck area.
This spontaneous report as received from a physician refers to multiple unspecified patients of unknown ages and gender. On unknown dates, the patients were vaccinated with unspecified doses of improperly stored ROTATEQ (lot# L027070, expiry date: 30-APR-2017; lot # L033694, expiry date: 16-JUN-2017) (route: oral) (incorrect product storage). The vaccine was stored at a temperature of 53.3 F for a time frame of 3 hours and 23 minutes. There was no previous temperature excursion. Digital data logger was involved. No adverse effects reported. The outcome of the events was unknown. This is one of the several reports received from the same reporter. Additional information has been requested.
p/1st set of immun (DTP/HIB/OPV) mom noted a high pitched different cry x 10 mins, also noted pt became stiff legged; this occurred w/in 1st 24 hrs of vax; no fever reported; s&s resolved & has done fine since that episode;
Information  has been received from a pharmacist concerning a patient who on 12-NOV-2007 was vaccinated with a .65 mL dose of ZOSTAVAX. On 12-NOV-2007 the patient developed a slight rash all over. No further information was reported. Unspecified medical attention was sought. The outcome was reported as recovered. There was no product quality complaint. Additional information has been requested.
Right arm hot,warm to touch, swollen from shoulder to under the elbo, pain in right elbow joint, temp of 102, informed patient to put ice on shoulder, arm and elbow. Recommended Tylenol, Ibuprofen for the pain.
Client had vaccine, left health district and 15 to 20 minutes later noticed jaw and neck muscles and, in general, all her muscles started to "tense up". Felt like "I coudn't breathe. I got shaky and weak. Almost like I was going into shock." She was driving and stopped in front of a Quick Care facility. Went inside and waited 1.5 hours. Symptoms abated. Left without being seen and returned immediately because symptoms returned. Again, left without being seen and went to personal doctor on 6/15/04. Could not be seen by doctor but was given prescription for "Thuja, 10gtts, three times per day by Dr. Client states doctor has "regular routine for reactions to hepatitis shots." Client states muscle tightening would return daily about mid afternoon. Client saw personal doctor 6/29/04 and was given "an IV drip". States she did not know what if was but "the active ingredient was hydrogen peroxide solution." Client reports feeling better today.
Injection site, surrounded by a two-inch by three-inch area is red, swollen, itchy and sensitive to pressure.
Only waited 30 minutes before eating after taking the doses; A spontaneous report was received from a physician assistant on 05OCT2022. It described a female patient (unknown age) who "only waited 30 minutes before eating after taking the doses" (PT: Product administration error). The patient took the Vivotif (typhoid vaccine live oral Ty21A) (lot number: unknown) for immunisation. It was reported that the patient took all four doses of Vivotif but only waited 30 minutes before eating after taking her doses. The outcome of the reported event was not applicable.  Action taken with Vivotif with respect to the reported event was not applicable.  No additional information was reported.  Company comment: It was reported that a consumer only waited 30 minutes before eating after taking the Vivotif doses (product administration error). Vivotif dose should be taken at least one hour before a meal. Considering the nature of the event, the causality of product administration error is assessed as not applicable with Vivotif. The case is considered non-serious as per medical assessment.; Sender's Comments: It was reported that a consumer only waited 30 minutes before eating after taking the Vivotif doses (product administration error). Vivotif dose should be taken at least one hour before a meal. Considering the nature of the event, the causality of product administration error is assessed as not applicable with Vivotif. The case is considered non-serious as per medical assessment.
I felt ill on the way home and became sick for 3 days. I had increased pain for an entire week. I had a horrific migraine and I was bedridden and the pain lasted a week. I suffer with chronic pain in hips and pelvis and it felt as though someone took a bat to my hips and pelvic area. it was horribly painful to walk, move, sit down, and so I took Advil every 4-6 hours, and used heating pads and ice.
I got my vaccine on 9/27/2021 around 5 pm in order to keep my job, which I started several months ago. The first night I felt mostly fine apart from soreness in my right arm where I was injected. I woke up the next day and felt like a truck hit me - exhausted, weak, fever/chills and tingly skin. I stayed home from work to rest and take care. Later that day the soreness in my upper right arm subsided and my hands felt very itchy, notably between my right thumb, index and middle fingers. I tried to avoid itching. I went back to work on Wednesday the 29th and felt mostly better apart from my arm still itching. Over the course of the next week the itching turned into a tingling/numb sensation that travelled from my fingers into my hand. As I write this now at the keyboard, my entire right arm is tingling and numb. Using my right hand for extended periods of time is a challenge. I am a healthy, 31 year old, active person with a plant-based diet and very health conscious. I'm worried these side effects have not gone away. I do not have a doctor yet and am awaiting health insurance.